Premium
Long‐term clinical observations for a biofunctionalized stent: Yet to deliver their theoretical benefits
Author(s) -
Nakamura Kenta,
Dean Larry S.
Publication year - 2018
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27663
Subject(s) - medicine , stent , taxus , paclitaxel , randomized controlled trial , endothelial progenitor cell , cardiology , progenitor cell , stem cell , cancer , botany , genetics , biology
Key Points Endothelial progenitor cells (EPCs) may allow accelerated and functional endothelialization of stents, theoretically reducing late stent complications as well reducing the duration of DAPT. In a pilot study of 193 patients at high risk of target vessel failure (TVF), the Genous EPC capturing stent (ESC) and TAXUS Liberté paclitaxel‐eluting second‐generation stent (PES) were similar at 5‐years. Events rates appear higher for ESC within the first‐year followed by higher rate of complications for PES during years 2–5. A larger randomized multi‐center trials powered for non‐inferiority of ECS to PES is underway.